Observational studyWorld journal of gastroenterology2018

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.

María Fernanda Guerra Veloz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.